SafeBoosC III Two-year Follow-up

CompletedOBSERVATIONAL
Enrollment

1,601

Participants

Timeline

Start Date

September 23, 2021

Primary Completion Date

October 19, 2024

Study Completion Date

October 19, 2024

Conditions
Deficits, NeurologicExtreme PrematurityBrain Damage
Interventions
OTHER

Treatment as usual + cerebral oximetry monitoring the first 72 hours of life

SafeBoosC - Safeguarding the Brain of Our Smallest Children - an Investigator-initiated Randomised, Blinded, Multinational, Phase II Feasibility Clinical Trial on Near-infrared Spectroscopy Monitoring Combined With Defined Treatment Guidelines Versus Standard Monitoring and Treatment as Usual in Premature Infants

Trial Locations (1)

Unknown

Righospitalet (The University Hospital, Copenhagen), Copenhagen

All Listed Sponsors
lead

Gorm Greisen

OTHER

NCT05134116 - SafeBoosC III Two-year Follow-up | Biotech Hunter | Biotech Hunter